NPM1 and acute myeloid leukemia: Focusing on NPM1-mutated AML, we perform clinical and genetic validation of the platform and nominate novel sensitizers to “7 + 3” daunorubicin (DNR) and cytarabine (AraC) combination chemotherapy in AML.